Pilot Study of Aerobic Exercise During Immune Checkpoint Inhibitor Therapy in Early-Stage TNBC

Inclusion criteria

• ✓. female and male participants 18 years or older and willing to provide Informed Consent
• ✓. clinical stage 2 or 3 TNBC (estrogen receptor and progesterone receptor ≤ 10% by immunohistochemistry (IHC) and human epidermal growth factor-2 (HER2) negative (IHC 0, IHC1+, or IHC 2+ with negative fluorescence in situ hybridization))
• ✓. Physically able to walk independently without assistive device and able to march in place for 30 seconds without assistive device
• ✓. Eastern Co-Operative Oncology Group (ECOG) Performance Status 0-1
• ✓. Planned receipt of neoadjuvant chemoICI therapy (carboplatin/taxane in combination with pembrolizumab; taxane options are weekly paclitaxel or every 3 week docetaxel)
• ✓. clearance to participate in the study by the patient's medical oncologist
• ✓. normal bone marrow function
• ✓. able to read/complete study forms/assessments and understand instructions in English